AdaptLLM/RCT · Datasets at Hugging Face

label stringclasses 5 values	text stringlengths 2 1.45k	metadata stringclasses 1 value
RESULTS	However , late loss ( 0.04 0.5 mm vs. 0.14 0.5 mm , p = 0.14 ) and binary restenosis rate ( 4.7 % vs. 9.5 % , p = 0.22 ) were very low and similar in both groups .
RESULTS	Clinical follow-up ( median 365 days ) was obtained in all ( 100 % ) patients .
RESULTS	Occurrences of the combined clinical outcome measure ( cardiac death , myocardial infarction , and target vessel revascularization ; 6 % vs. 8 % ; hazard ratio [ HR ] : 0.76 ; 95 % CI : 0.26 to 2.18 , p = 0.6 ) and the need for target vessel revascularization ( 2 % vs. 6 % ; HR : 0.32 : 95 % CI : 0.07 to 1.59 , p = 0.17 ) were similar in the 2 groups .
CONCLUSIONS	In patients with BMS-ISR , both DEB and EES provided excellent clinical results with a very low rate of clinical and angiographic recurrences .
CONCLUSIONS	However , compared with DEB , EES provide superior late angiographic findings .
CONCLUSIONS	( Restenosis Intra-stent of Bare Metal Stents : Paclitaxel-eluting Balloon vs. Everolimus-eluting Stent [ RIBS V ] ; NCT01239953 ) .
BACKGROUND	Irregularity measures have been suggested as risk indicators in patients with atrial fibrillation ( AF ) ; however , it is not known to what extent they are affected by commonly used rate-control drugs .
BACKGROUND	We aimed at evaluating the effect of metoprolol , carvedilol , diltiazem , and verapamil on the variability and irregularity of the ventricular response in patients with permanent AF .
RESULTS	Sixty patients with permanent AF were part of an investigator-blind cross-over study , comparing 4 rate-control drugs ( diltiazem , verapamil , metoprolol , and carvedilol ) .
RESULTS	We analyzed five 20-minute segments per patient : baseline and the 4 drug regimens .
RESULTS	On every segment , heart rate ( HR ) variability and irregularity of RR series were computed .
RESULTS	The variability was assessed as standard deviation , pNN20 , pNN50 , pNN80 , and rMSSD .
RESULTS	The irregularity was assessed by regularity index , approximate ( ApEn ) , and sample entropy .
RESULTS	A significantly lower HR was obtained with all drugs , the HR was lowest using the calcium channel blockers .
RESULTS	All drugs increased the variability of ventricular response in respect to baseline ( as an example , rMSSD : baseline 171 47 milliseconds , carvedilol 229 58 milliseconds ; P < 0.05 vs. baseline , metoprolol 226 66 milliseconds ; P < 0.05 vs. baseline , verapamil 228 84 ; P < 0.05 vs. baseline , diltiazem 256 87 milliseconds ; P < 0.05 vs. baseline and all other drugs ) .
RESULTS	Only - blockers significantly increased the irregularity of the RR series ( as an example , ApEn : baseline 1.86 0.13 , carvedilol 1.92 0.09 ; P < 0.05 vs. baseline , metoprolol 1.93 0.08 ; P < 0.05 vs. baseline , verapamil 1.86 0.22 ns , diltiazem 1.88 0.16 ns ) .
CONCLUSIONS	Modification of AV node conduction by rate-control drugs increase RR variability , while only - blockers affect irregularity .
OBJECTIVE	Among patients with quiescent ulcerative colitis ( UC ) , lower fecal concentrations of calprotectin are associated with lower rates of relapse .
OBJECTIVE	We performed an open-label , randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin ( FC ) in patients with quiescent UC .
METHODS	We screened 119 patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores , FC > 50 g/g , and intake of no more than 3 g/day mesalamine .
METHODS	Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine ( 2.4 g/day ) for 6 weeks ; 52 participants were then randomly assigned ( 1:1 ) to a group that continued its current dose of mesalamine ( controls , n = 26 ) or a group that increased its dose by 2.4 g/day for 6 weeks ( n = 26 ) .
METHODS	The primary outcome was continued remission with FC < 50 g/g .
METHODS	Secondary outcomes were continued remission with FC < 100 g/g or < 200 g/g ( among patients with pre-randomization values above these levels ) .
RESULTS	The primary outcome was achieved by 3.8 % of controls and 26.9 % of the dose escalation group ( P = .0496 ) .
RESULTS	More patients in the dose escalation group reduced FC to below 100 g/g ( P = .04 ) and 200 g/g ( P = .005 ) .
RESULTS	Among the patients who were still in remission after the randomization phase , clinical relapse occurred sooner in patients with FC > 200 g/g compared with those with FC < 200 g/g ( P = .01 ) .
CONCLUSIONS	Among patients with quiescent UC and increased levels of FC , increasing the dose of mesalamine by 2.4 g/day reduced fecal concentrations of calprotectin to those associated with lower rates of relapse .
CONCLUSIONS	Clinicaltrials.gov number : NCT00652145 .
BACKGROUND	Despite standard statin therapy , a majority of patients retain a high `` residual risk '' of cardiovascular events .
OBJECTIVE	The aim of this study was to evaluate the effects of ezetimibe plus atorvastatin versus atorvastatin monotherapy on the lipid profile and coronary atherosclerosis in Japanese patients who underwent percutaneous coronary intervention ( PCI ) .
METHODS	This trial was a prospective , randomized , controlled , multicenter study .
METHODS	Eligible patients who underwent PCI were randomly assigned to atorvastatin alone or atorvastatin plus ezetimibe ( 10 mg ) daily .
METHODS	Atorvastatin was uptitrated with a treatment goal of low-density lipoprotein cholesterol ( LDL-C ) < 70 mg/dl .
METHODS	Serial volumetric intravascular ultrasound was performed at baseline and again at 9 to 12 months to quantify the coronary plaque response in 202 patients .
RESULTS	The combination of atorvastatin/ezetimibe resulted in lower levels of LDL-C than atorvastatin monotherapy ( 63.2 16.3 mg/dl vs. 73.3 20.3 mg/dl ; p < 0.001 ) .
RESULTS	For the absolute change in percent atheroma volume ( PAV ) , themean difference between the 2 groups ( -1.538 % ; 95 % confidence interval [ CI ] : -3.079 % to 0.003 % ) did not exceedthe pre-defined noninferiority margin of 3 % , but the absolute change in PAV did show superiority for the dual lipid-lowering strategy ( -1.4 % ; 95 % CI : -3.4 % to -0.1 % vs. -0.3 % ; 95 % CI : -1.9 % to 0.9 % with atorvastatin alone ; p = 0.001 ) .
RESULTS	For PAV , a significantly greater percentage of patients who received atorvastatin/ezetimibe showed coronary plaque regression ( 78 % vs. 58 % ; p = 0.004 ) .
RESULTS	Both strategies had acceptable side effect profiles , with a low incidence oflaboratory abnormalities and cardiovascular events .
CONCLUSIONS	Compared with standard statin monotherapy , the combination of statin plus ezetimibe showed greater coronary plaque regression , which might be attributed to cholesterol absorption inhibition-induced aggressive lipid lowering .
CONCLUSIONS	( Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound [ PRECISE-IVUS ] ; NCT01043380 ) .

RESULTS

However , late loss ( 0.04 0.5 mm vs. 0.14 0.5 mm , p = 0.14 ) and binary restenosis rate ( 4.7 % vs. 9.5 % , p = 0.22 ) were very low and similar in both groups .

RESULTS

Clinical follow-up ( median 365 days ) was obtained in all ( 100 % ) patients .

RESULTS

Occurrences of the combined clinical outcome measure ( cardiac death , myocardial infarction , and target vessel revascularization ; 6 % vs. 8 % ; hazard ratio [ HR ] : 0.76 ; 95 % CI : 0.26 to 2.18 , p = 0.6 ) and the need for target vessel revascularization ( 2 % vs. 6 % ; HR : 0.32 : 95 % CI : 0.07 to 1.59 , p = 0.17 ) were similar in the 2 groups .

CONCLUSIONS

In patients with BMS-ISR , both DEB and EES provided excellent clinical results with a very low rate of clinical and angiographic recurrences .

CONCLUSIONS

However , compared with DEB , EES provide superior late angiographic findings .

CONCLUSIONS

( Restenosis Intra-stent of Bare Metal Stents : Paclitaxel-eluting Balloon vs. Everolimus-eluting Stent [ RIBS V ] ; NCT01239953 ) .

BACKGROUND

Irregularity measures have been suggested as risk indicators in patients with atrial fibrillation ( AF ) ; however , it is not known to what extent they are affected by commonly used rate-control drugs .

BACKGROUND

We aimed at evaluating the effect of metoprolol , carvedilol , diltiazem , and verapamil on the variability and irregularity of the ventricular response in patients with permanent AF .

RESULTS

Sixty patients with permanent AF were part of an investigator-blind cross-over study , comparing 4 rate-control drugs ( diltiazem , verapamil , metoprolol , and carvedilol ) .

RESULTS

We analyzed five 20-minute segments per patient : baseline and the 4 drug regimens .

RESULTS

On every segment , heart rate ( HR ) variability and irregularity of RR series were computed .

RESULTS

The variability was assessed as standard deviation , pNN20 , pNN50 , pNN80 , and rMSSD .

RESULTS

The irregularity was assessed by regularity index , approximate ( ApEn ) , and sample entropy .

RESULTS

A significantly lower HR was obtained with all drugs , the HR was lowest using the calcium channel blockers .

RESULTS

All drugs increased the variability of ventricular response in respect to baseline ( as an example , rMSSD : baseline 171 47 milliseconds , carvedilol 229 58 milliseconds ; P < 0.05 vs. baseline , metoprolol 226 66 milliseconds ; P < 0.05 vs. baseline , verapamil 228 84 ; P < 0.05 vs. baseline , diltiazem 256 87 milliseconds ; P < 0.05 vs. baseline and all other drugs ) .

RESULTS

Only - blockers significantly increased the irregularity of the RR series ( as an example , ApEn : baseline 1.86 0.13 , carvedilol 1.92 0.09 ; P < 0.05 vs. baseline , metoprolol 1.93 0.08 ; P < 0.05 vs. baseline , verapamil 1.86 0.22 ns , diltiazem 1.88 0.16 ns ) .

CONCLUSIONS

Modification of AV node conduction by rate-control drugs increase RR variability , while only - blockers affect irregularity .

OBJECTIVE

Among patients with quiescent ulcerative colitis ( UC ) , lower fecal concentrations of calprotectin are associated with lower rates of relapse .

OBJECTIVE

We performed an open-label , randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin ( FC ) in patients with quiescent UC .

METHODS

We screened 119 patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores , FC > 50 g/g , and intake of no more than 3 g/day mesalamine .

METHODS

Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine ( 2.4 g/day ) for 6 weeks ; 52 participants were then randomly assigned ( 1:1 ) to a group that continued its current dose of mesalamine ( controls , n = 26 ) or a group that increased its dose by 2.4 g/day for 6 weeks ( n = 26 ) .

METHODS

The primary outcome was continued remission with FC < 50 g/g .

METHODS

Secondary outcomes were continued remission with FC < 100 g/g or < 200 g/g ( among patients with pre-randomization values above these levels ) .

RESULTS

The primary outcome was achieved by 3.8 % of controls and 26.9 % of the dose escalation group ( P = .0496 ) .

RESULTS

More patients in the dose escalation group reduced FC to below 100 g/g ( P = .04 ) and 200 g/g ( P = .005 ) .

RESULTS

Among the patients who were still in remission after the randomization phase , clinical relapse occurred sooner in patients with FC > 200 g/g compared with those with FC < 200 g/g ( P = .01 ) .

CONCLUSIONS

Among patients with quiescent UC and increased levels of FC , increasing the dose of mesalamine by 2.4 g/day reduced fecal concentrations of calprotectin to those associated with lower rates of relapse .

CONCLUSIONS

Clinicaltrials.gov number : NCT00652145 .

BACKGROUND

Despite standard statin therapy , a majority of patients retain a high `` residual risk '' of cardiovascular events .

OBJECTIVE

The aim of this study was to evaluate the effects of ezetimibe plus atorvastatin versus atorvastatin monotherapy on the lipid profile and coronary atherosclerosis in Japanese patients who underwent percutaneous coronary intervention ( PCI ) .

METHODS

This trial was a prospective , randomized , controlled , multicenter study .

METHODS

Eligible patients who underwent PCI were randomly assigned to atorvastatin alone or atorvastatin plus ezetimibe ( 10 mg ) daily .

METHODS

Atorvastatin was uptitrated with a treatment goal of low-density lipoprotein cholesterol ( LDL-C ) < 70 mg/dl .

METHODS

Serial volumetric intravascular ultrasound was performed at baseline and again at 9 to 12 months to quantify the coronary plaque response in 202 patients .

RESULTS

The combination of atorvastatin/ezetimibe resulted in lower levels of LDL-C than atorvastatin monotherapy ( 63.2 16.3 mg/dl vs. 73.3 20.3 mg/dl ; p < 0.001 ) .

RESULTS

For the absolute change in percent atheroma volume ( PAV ) , themean difference between the 2 groups ( -1.538 % ; 95 % confidence interval [ CI ] : -3.079 % to 0.003 % ) did not exceedthe pre-defined noninferiority margin of 3 % , but the absolute change in PAV did show superiority for the dual lipid-lowering strategy ( -1.4 % ; 95 % CI : -3.4 % to -0.1 % vs. -0.3 % ; 95 % CI : -1.9 % to 0.9 % with atorvastatin alone ; p = 0.001 ) .

RESULTS

For PAV , a significantly greater percentage of patients who received atorvastatin/ezetimibe showed coronary plaque regression ( 78 % vs. 58 % ; p = 0.004 ) .

RESULTS

Both strategies had acceptable side effect profiles , with a low incidence oflaboratory abnormalities and cardiovascular events .

CONCLUSIONS

Compared with standard statin monotherapy , the combination of statin plus ezetimibe showed greater coronary plaque regression , which might be attributed to cholesterol absorption inhibition-induced aggressive lipid lowering .

CONCLUSIONS

( Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound [ PRECISE-IVUS ] ; NCT01043380 ) .